Funding for this research was provided by:
Department of Oncology, Cancer Centre of Southeastern Ontario at Kingston General Hospital, Queen's University (NA)
Text and Data Mining valid from 2019-11-01
Received: 29 July 2019
Accepted: 22 September 2019
First Online: 1 November 2019
Ethics approval and consent to participate
: This work was performed with the approval of the Health Sciences Research Ethics Board of Queen’s University, Canada, reference number DBMS-002-11. The MA.12 trial was approved by local research ethics boards (Queen’s University DBMS-049-15), and participants provided written informed consent.
: Not applicable.
: Dr. Christopher Mueller is a co-holder of a patent on the analysis of glucocorticoid receptor promoter methylation in breast cancer. There is no current financial activity related to this patent. The other authors declare that they have no competing interests.